Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 20, Number 4—April 2014


High Rates of Antimicrobial Drug Resistance Gene Acquisition after International Travel, the Netherlands

Christian J.H. von Wintersdorff, John Penders, Ellen E. Stobberingh, Astrid M.L. Oude Lashof, Christian J.P.A. Hoebe, Paul H.M. Savelkoul, and Petra F.G. WolffsComments to Author 
Author affiliations: Maastricht University Medical Center, Maastricht, the Netherlands (C.J.H. von Wintersdorff, J. Penders, E.E. Stobberingh, A.M.L. Oude Lashof, C.J.P.A. Hoebe, P. Savelkoul, P.H.M. Wolffs); South Limburg Public Health Service, Geleen, the Netherlands (C.J.P.A. Hoebe)

Main Article

Table 2

Characteristics of 122 travelers observed for rates of antimicrobial resistance gene acquisition after international travel, the Netherlands, 2010–2012*

Characteristic No. (%)
M 51 (41.8)
F 71 (58.2)
Clinical finding
Traveler’s diarrhea 45 (36.9)
Antimicrobial drug use 15 (12.3)
Region visited
Southeast Asia 28 (23.0)
Indian subcontinent 31 (25.4)
Northern Africa 16 (13.1)
Southern Africa 17 (13.9)
Southern Europe 6 (4.9)
Central America 4 (3.3)
South America 6 (4.9)
Other/multiple 7 (5.7)

*Median age, y (range) of travelers was 42.7 (18–72) and median travel duration, (range) was 21.0 (5-20) months. Countries in respective regions are as follows: Southeast Asia (Indonesia, Philippines, Malaysia, Myanmar, Cambodia, Thailand, Vietnam), Indian subcontinent (India, Nepal, Sri Lanka), northern Africa (Canary Islands, Egypt, Gambia, Ghana, Togo, Morocco, Senegal, Uganda), southern Africa (Namibia, Kenya, Tanzania, Zanzibar, Mauritius, South Africa), Central America (Panama, Costa Rica, Mexico), South America (Argentine, Bolivia, Brazil, Columbia, Peru, Suriname), southern Europe (Croatia, Spain, Turkey), other (Australia, Fiji, New Zealand, Oman).

Main Article

*These authors contributed equally to this article and are co–first authors.